SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers to enable imaging of disease biomarkers in the eye, today announced it has launched a Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.

圣地亚哥，2023年11月2日（GLOBE NEWSWIRE）-Amydis Inc.，一家私营临床阶段公司，开创了一个眼部示踪剂平台，能够对眼睛中的疾病生物标志物进行成像，今天宣布启动第二阶段临床其新型视网膜示踪剂AMDX-2011P的计划，用于检测青光眼患者的β淀粉样蛋白。

Glaucoma is an age-related neurodegenerative disease associated with the loss of retinal ganglion cells and characteristic vision loss. It is the leading cause of irreversible blindness worldwide, projected to affect 112 million people by 2040. The rate of glaucoma progression can vary across patients; and diagnosis, defining prognosis, establishing progression, and developing optimal interventions can be challenging.

青光眼是与视网膜神经节细胞丢失和特征性视力丧失有关的与年龄有关的神经退行性疾病。它是全球不可逆转失明的主要原因，预计到2040年将影响1.12亿人。青光眼进展速度因患者而异；和诊断，确定预后，建立进展和制定最佳干预措施可能具有挑战性。

Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tests can evaluate visual loss associated with the disease. However, the relationship between and time of onset of these structural, vascular and visual function changes are not well established.

多种诊断测试可检测与青光眼相关的视网膜结构和血管变化，而视觉功能测试可评估与疾病相关的视力丧失。然而，这些结构，血管和视觉功能变化的发生与时间之间的关系尚未确定。

The addition of another in-vivo diagnostic modality such as detection of molecular changes would add significant clarity to the pathogenesis of the disease. Converging data indicate that amyloid beta, best known for its association with Alzheimer’s disease, is a key factor in glaucoma pathogenesis. The extensive links between Alzheimer’s disease and glaucoma have prompted the notion that glaucoma is an “ocular Alzheimer’s disease”.

增加另一种体内诊断方式，例如检测分子变化，将为疾病的发病机理增加明显的清晰度。汇总数据表明，β淀粉样蛋白与阿尔茨海默病最为人所知，是青光眼发病机制中的关键因素。阿尔茨海默氏病和青光眼之间的广泛联系促使人们认为青光眼是“眼部阿尔茨海默氏病”。

The Amydis patented retinal tracer, AMDX-2011P, is a small molecule designed to enable detection and quantification of amyloid beta deposits in the retina using imaging devices already incorporated as part of a patient’s standard office visit. Thus, as a widely adoptable, simple a.

Amydis专利的视网膜示踪剂AMDX-2011P是一种小分子，旨在使用已作为患者标准办公室访问一部分的成像设备检测和定量视网膜中的淀粉样β沉积物。因此，作为一个广泛采用的，简单的a。